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Imaginary Worlds and the Institute for Clinical and Economic Review (ICER) Evidence Report: 
Targeted Immune Modulators for Rheumatoid Arthritis  
Paul C Langley, PhD, Adjunct Professor, University of Minnesota 
 
Abstract 
In April 2017, the Institute for Clinical and Economic Review (ICER) issued its evidence report on the value of targeted immune 
modulators (TIMs) in rheumatoid arthritis. The report made the case that for the TIMs to be accepted for formulary placement in the 
US, where notional willingness-to-pay thresholds are the ICER gateway criteria, manufacturers should be prepared to offer substantial 
unit price discounts. The purpose of this commentary is to make the case that the methodology underpinning the ICER claims for value 
assessment does not meet the required standards of normal science.  None of the claims made for clinical and comparative cost-
effectiveness are credible, evaluable and replicable. As such, formulary committees have no idea whether ICER recommendations are 
right or even if they are wrong. They are, in fact, immune to failure and should be rejected. Utilizing ICER claims generated by simulated 
projections, this review points out that it is entirely possible to justify the current WAC or net pricing structure of TIMS. The review 
concludes that if ICER is to contribute to the successful formulary placement of drugs and devices the methodology for pricing 
recommendation should be re-assessed. As it stands, questions must be raised regarding recommendations for, possibly unnecessary, 
price discounts. ICER needs to develop an assessment framework that focuses on developing claims for competing therapies that are 
robust, evaluable and replicable together with recommendations on how these claims are to be evaluated in a timeframe meaningful 
to health care decision makers. 
 




In April 2017, the Institute for Clinical and Economic Review 
(ICER) issued an evidence report for the comparative clinical 
effectiveness, cost-effectiveness and value of targeted immune 
modulators (TIMs) for patients with moderately-to-severely 
active rheumatoid arthritis (RA) despite prior treatment with 
conventional disease-modifying anti-rheumatic drugs 
(cDMARDs) 1. The purpose of this commentary is to consider 
the merits or otherwise of the claims made by ICER for the 
lifetime cost effectiveness of TIMS and the consequent 
recommendations, based upon lifetime cost-per quality (QALY) 
projections, for value-based benchmark prices for the TIMs in 
treatment practice.   
 
This commentary follows upon two previous commentaries of 
ICER evidence reports in heart failure and multiple sclerosis 2 3. 
Together these commentaries are part of an ongoing series of 
commentaries published in the University of Minnesota peer-  
reviewed journal INNOVATIONS in Pharmacy that have 
provided an ongoing critique of current standards in health 
technology assessment 4. Previous publications and formulary 
evaluation commentaries in this series have made clear that in 
putting to one side a commitment to the standards of normal  
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science, where modeled claims or hypotheses are credible, 
evaluable and replicable, decision-makers in health care have a 
limited and potentially misleading evidence base for effective 
formulary decisions. A lifetime cost-per-QALY model is not 
designed to generate evaluable claims. It is a construct that is 
defended by its sufficient correspondence to a perceived 
reality. Validation focuses on the core model and its 
assumptions. Whether or not the model can support evaluable 
claims and whether or not these claims could ever be evaluated 
are apparently irrelevant.  
 
The argument put forward in these commentaries is that 
advocates of models that are intended to ‘inform’ decision 
makers in health care systems (whatever that means) rather 
than establish a practical research program, put to one side a 
commitment to standards that have been in place since the 
seventeenth century in favor of what has been described as 
pseudoscience 5. In an effort to avoid this characterization, 
guidelines have been proposed by the Program in Social and 
Administrative Pharmacy at the University of Minnesota that 
reject imaginary constructs in favor of credible, evaluable and 
replicable claims; claims which apply equally well to clinical 
outcomes as well as those for comparative cost-effectiveness 
and budget impact 6 7. Formulary submissions are to be 
supported by protocols to detail how the claims are to be 
evaluated and reported. This requirement is not new. It was put 
forward as a standard over ten years ago in formulary 
submission guidelines developed for the Wellpoint (now 
Anthem) health system in the US 8 9.   
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The recent commentary on the ICER evidence review in heart 
failure drugs pointed out,  perhaps not surprisingly, that 
different models can generate quite different perspectives on 
the presumption of ‘cost-effectiveness’ 2. If modeled claims are 
to be useful for formulary decision making, then we need to 
eschew ‘black box’ lifetime cost-per-QALY models with non-
evaluable claims in favor of transparent and public domain 
accessible models that yield credible, evaluable and replicable 
claims that can support defensible product placement and 
pricing decisions. A similar conclusion was reached, again not 
surprisingly, in the more recent review of the ICER evidence 
assessment for multiple sclerosis interventions 3.  The claims 
made for comparative effectiveness and value were not 
acceptable because they were immune to failure.  The review 
concluded that if ICER models are to contribute to improving 
our understanding of the effectiveness and costs of DMTs then 
they should be evaluable in the short-term to allow feedback to 
formulary committees in a meaningful timeframe. 
 
If ICER is to contribute to formulary decision making then the 
primary objective must be to support the assessment of robust, 
evaluable and replicable claims for therapy interventions. The 
purpose of the present commentary is to point out the 
limitations of the present ICER methodology and to suggest 
how these objectives might be met through eschewing lifetime 
modeled claims and focusing instead of modeled claims, in this 
case for TIM initiated treatment pathways, that are meaningful.  
 
The ICER Evidence Review 
For present purposes the focus is on: (i) outcomes of the ICER 
assessment of the comparative clinical efficacy of targeted 
immune modulator treatment pathways (TIMs); (ii) the ICER 
modeled claims for long term cost-effectiveness of the TIMs; 
and (iii) the claims for TIM value-based benchmark prices. The 
therapies comprise: five subcutaneous TIMs (adilumumab, 
certolizumab, etanercept, golimumab, sarilumab); two 
subcutaneous or intravenous TIMs (abatacept and tocilizumab), 
two intravenous TIMs (infliximab, rituximab) and two oral TIMs 
(baricitrinib, tofacitinib). At the time of the evidence review 
publication two had yet to receive FDA approval: sarilumab and 
baricitrinib. 
 
Comparative Efficacy Claims 
As the ICER evidence review points out, the claims for 
comparative product performance should be seen in the 
context of a number of recent reviews of TIMs, together with 
network meta-analyses of the biologic disease modifying anti-
rheumatic drugs (bDMARDS). ICER provides a brief summary of 
five evaluations (Appendix E) of TIMS in patients aged 18 years 
and over with moderate to severe rheumatoid arthritis and an 
inadequate response to or intolerance of cDMARDs.  These are 
the NICE technology assessment report 10; the AHRQ 
comparative effectiveness review 11; two Cochrane reviews 12 
13; and a Canadian Agency for Drugs and Technologies in Health 
(which is presently being updated) 14  15. The NICE evidence 
review group report is of particular note  as it includes not only 
critiques of manufacturer’s submissions to support NICE 
assessment and recommendations, but a comprehensive 
network meta-analysis and scenario evaluations to support a 
lifetime cost effectiveness model which, as might be expected., 
anticipates and mirrors the model presented in the ICER 
evidence review. At the same time, the focus on the UK is of 
interest because it offers insight into the process by which the 
assessment presented the review group was evaluated by NICE 
and factored into the technology appraisal guidance issued by 
NICE in January 2016 16.  
 
ICER estimates of comparative clinical effectiveness were based 
on published papers as well as abstracts/presentations. These 
comprised 132 reports, 67 RCTs and 17 observational studies. 
Of the RCTs evaluated, 60 focused on TIM combination therapy 
with methotrexate or other cDMARDs, five on TIM 
monotherapy and two with both combination and 
monotherapy. Outcomes in the network meta-analysis 
included the ACR criteria for 20%, 50% and 70% response and, 
in a more limited data set, radiographic progression. Individual 
product analysis found that all TIMS in combination with a 
cDMARD produced statistically and clinically improved 
symptom response improvements and associated outcomes 
compared to cDMARDs as monotherapy. All were between two 
and three times likely to achieve a ≥ACR20 response. The 
overall incidence of serious infections, deaths and serious 
adverse events were comparable between treatments. 
 
With only eight head-to-head comparisons of the TIMs of 
interest the network meta-analysis was driven largely by 
indirect comparisons. Even so, findings were consistent with 
those for head-to-head studies as well as assessments of 
relative differences in ACR response in comparison to cDMARD 
therapy. The network meta-analysis results were also 
consistent with findings from other recent assessments. 
Importantly, however, in the network meta-analysis none of 
the comparisons between the individual TIMS differed at 
conventional decision levels. 
 
In pointing to controversies and uncertainties in drawing 
inferences for therapy options and therapy sequencing, the 
ICER review points to the absence of data on the long-term 
effects of initial DMARD treatment, in particular the timing of 
treatment switch decisions. The ICER review notes that 
comparisons of TIM combination therapy or monotherapy with 
cDMARDS do not provide an evidence base for comparing 
treatment sequencing options. 
  
The ICER Model 
The ICER sequential treatment or pathway cohort model is 
intended to provide a framework for assessing the long-term 
cost-effectiveness of each of the TIMs as combination therapy  
detailed in the clinical review relative to cDMARDs as 
monotherapy. The model parameters are taken from the 
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network meta-analysis and the published literature. The 
simulated outcomes are: (i) discounted lifetime total payer 
costs; (ii) life years lived; (iii) quality adjusted life years (QALYs) 
and incremental cost-effectiveness ratios (ICERs). 
 
The simulation is for a hypothetical cohort of patients with a 
tracking simulation from a selected TIM initial combination 
therapy to death (in the model approximately 16-17 years). 
Treatment was considered effective if the patient achieved an 
ACR≥ 20. A model treatment cycle of six months was assumed 
for all therapy initiations and sequences. Beyond the first six 
months patients were assumed to discontinue therapy only due 
to adverse events. If the patient failed to respond to initial TIM  
therapy the stimulation required switching to up to three times: 
first, within the same TIM class; (ii) to a different TIM class; and 
then (iii) to palliative care with cDMARDs. The level of ACR 
response determined quality of life improvements; quality of 
life was degraded if patients were on cDMARDs. Each TIM was 
assumed to be used in combination with methotrexate.  
 
The base-case simulation (which is the focus here) assumed a 
hypothetical cohort with a mean age of 55 years, 79% female, 
84% Caucasian, and a mean weight of 170 pounds. Base HAQ 
prior to cDMARD benefit was 1.7 (range 1.37 to 2.03) and a 
baseline mTSS of 54 (SD:64). Age and gender were used to 
estimate mortality risk, with mean weight to calculate dosing. 
Costs were categorized as: (i) drug acquisition costs (WAC 
discounted to give a net price); (ii) administration and 
monitoring costs; (iii) health care utilization costs (e.g., 
hospitalizations, office visits); (iv) severe event costs; and, in an 
extended analysis, (v) productivity costs. Clinical events were 
captured by (i) response to treatment by ACR score and adverse 
event discontinuations; (ii) mortality (i.e., HAQ as a predictor or 
mortality); and (iii) utilities. Utilities were captured by mapping 
from the HAQ score. The model was subject to one way 
sensitivity analysis and probabilistic sensitivity analyses 
together with multiple scenario analyses.   
 
Model Outcomes 
The base case model results for (i) total cost; (ii) proportion of 
drug costs to total costs; (iii) life years; (iv) QALYs and (v) QALY 
days gained vs. average QALY are presented in Table 1 for each 
assumed TIM initiated pathway. Simulated (i.e., imaginary) 
lifetime total pathway costs ranged from $424,674 (tocilizumab 
iv) to $583,449 (etanercept). The TIM average ratio of drug to 
total costs was 79.50% (range 77.55 to 80.77%). Simulated 
average life years lived were 16.82 years (range 16.78 – 16.94 
years [or 58 days]) versus 16.16 years for cDMARDs. Simulated 
average TIM pathway QALYs were 12.79 (range 12.69 – 13.12 
QALYs [or 157 quality adjusted days]) versus 10.69 QALYs for 
cDMARDs. 
  
Willingness-to-Pay Threshold Analysis 
This similarity in QALY outcomes for the various TIM initiated 
treatment pathways is to be expected from the model structure 
and, in the second and third therapy sequences, the bundling 
together of TIMs by class. Even so, there are substantial 
differences between the TIMs in both their WAC price and their 
assumed net discounted prices. This leads to different 
estimates of the unit prices required to achieve $50,000, 
$100,000 and $150,00o QALY thresholds together with 
estimates of the range of discounts from WAC to achieve these 
thresholds. The base case results for this analysis are achieved 
through adjusting the respective ICER pairwise comparisons 
between the results for the individual TIM therapy pathway 
with the cDMARD reference treatment pathway. As an 
example, in the case of adalimumab, the market leader, the 
current WAC price per unit is $2,220.62 and the net price 
$1,554.43. To achieve the willingness-to-pay thresholds ICER 
would recommend a unit price of $373.06 for the $50,000 
threshold, $699.49 for the $100,000 threshold and $1,010.38 
for the $150,000 threshold. These translate to discounts from 
WAC in the range 55% to 83%. 
 
Discussion 
The principal objective of the ICER modeling is to generate 
recommendations to support discounting of drug costs by 
manufacturers to ensure that they fall within arbitrary 
willingness-to-pay cost per QALY thresholds. To justify these 
discounts, the case rests upon a modeled lifetime cost-per-
QALY simulation that projects from a short term evidence base 
with efficacy claims for the competing TIMs created by a 
network meta-analysis. A network analysis that rests principally 
on indirect comparisons, the outcomes of which are best seen 
as hypotheses themselves for comparative treatment effects 
across the TIM therapy options.  
 
From the perspective of the standards of normal science, the 
principal objection to claims for the impact and costs of 
competing therapy interventions from the ICER and similar 
models is that the claims made for treatment pathway 
outcomes are immune to failure 17. This is the inevitable  result 
of employing a modeled lifetime perspective with an assumed 
treatment pathway sequence of fixed interval therapy 
switching. The reader has no idea whether the claims for the 
costs of treatment, years lived or QALYs are right or even if they 
are wrong; indeed, the reader will never know. As such, despite 
claims that they may, in some sense, be sufficiently 
representative of the model builders’ perception a present and 
future reality to be taken seriously, they are entirely imaginary 
constructs. They fail to meet standards for generating evaluable 
hypotheses to establish product-specific value claims that can 
be assessed and replicated in target treating populations.  
 
As argued in previous commentaries in this series, non-
evaluable claims generated by lifetime cost-utility or reference 
case models, rejects experimentation through hypothesis 
testing or systematic observation in favor of relativism and the 
acceptance of constructed evidence 18 . The ‘gold standard’ of 
experimentation has been accepted for the last 350 years, 
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exemplified in the motto of the Royal Society  (founded 1660; 
Royal Charter 1662): nullius in verba (take no man’s word for it). 
As stated on the Royal Society website, this motto ‘is an 
expression of the determination of Fellows to withstand the 
domination of authority and to verify all statements by an 
appeal to the facts determined by experiment’ 19. 
 
A Multiverse of Models and Modeled Scenarios 
If we were to suspend disbelief in the ICER methodology and 
subscribe to the information value of evidence from 
constructing imaginary worlds, the question then becomes: 
from a potential multiverse of models and modeled scenarios 
which one do we chose?  Are all models equally valid? Do we 
only choose models that meet arbitrary reference case 
standards? Do we only choose models that mandate a specific 
generic HRQoL measure? Do we only choose models that 
mandate a specific disease-specific HRQoL measure? Can we 
map HRQoL utilities from clinical markers? Do we only choose 
models that assume a minimum sequence of options in therapy 
sequencing over a patient’s lifetime? How do we justify future 
claims for clinical status when they are predicated on multiple 
sequential therapy switches for which there are no data? How 
do we accommodate long-term response to biologics in 
rheumatoid arthritis when the majority of patients have 
discontinued bDMARD therapy within two years? Can we justify 
claims for future costs of treatment when the possibility of 
manufacturers following a strategy of substantial annualized 
price increases is ignored? Does everyone subscribe to 
willingness-to-pay thresholds? Should our criterion be that if a 
modeled is judged ‘sufficiently’ realistic then the claims will 
necessarily follow? Why should formulary committees 
subscribe to claims generated by imaginary simulations? 
 
We could, of course, brush these questions to one side and take 
the relativist position on constructed evidence. As long as the 
community of scholars in health technology assessment, 
including ICER, agree that reference case modeling is 
acceptable then why should we disagree? The latest CADTH 
guidelines, for example, are quite explicit in their rejection of 
the standards of normal science in favor of lifetime-cost-per-
QALY claims: Economic evaluations are designed to inform 
decisions. As such, they are distinct from conventional research 
activities, which are designed to test hypotheses 20. The latest 
version of these guidelines, released March 2017, has been 
reviewed as part of this commentary series 21. The 
recommendation, which is unlikely to be accepted given the 
investment in imaginary worlds by professional groups and 
agencies such as CADTH is to abandon a relativist position and 
focus on evaluable and replicable clinical and cost-outcomes 
claims. 
  
In any event, whether we agree or disagree that technology 
assessments should focus on hypothesis testing, it is worth 
considering a number of the assumptions that underpin the 
ICER model structure and claims for lifetime cost-effectiveness 
of the TIMs. This does not endorse the construction of 
imaginary worlds. Rather, it points to the flexibility we always 
have in building imaginary worlds and for ongoing disputes 
between competing model builders 22.  
 
The Lifetime Horizon 
As noted, the adoption of a model framework that tracks 
patients through a series of switching algorithms over the 
lifetime of a hypothetical cohort ensures that the claims made 
are immune to failure. At the same time, there is no account of 
the potential impact of products, which may now be in phase 2 
or phase 3 of product development, on prospective therapy 
switching and persistence with current therapies. As this would, 
presumably, admit of a range of market entry scenarios, pricing 
and switching options, it would be foolhardy to attempt such as 
exercise.  
 
The model builder is faced with two options, allow simplified 
market entry of competitor scenario(s) or admit that this 
possibility has been discounted. Neither are likely to appeal to 
decision makers. A more reasonable approach would be to 
admit the potential for new entrants and focus on short term 
credible and evaluable claims. Support for these claims would 
potentially put existing products in a stronger evidentiary 
position for continued formulary placement and 
patient/physician acceptance. New entrants would have to 
demonstrate, again with credible and evaluable claims, their 
comparative benefits and harms to those already accepted as 
integral to treatment pathway decisions. 
 
The fact that agencies such as NICE in the UK and the PBAC in 
Australia, among others, have adopted a reference case 
lifetime cost-per-QAY model that excludes consideration of  
from, in this case the pipeline of new compounds for target 
rheumatoid arthritis patients, is no reason to accept uncritically 
the same reference framework for modeling claims in the US 
market - let alone the underlying acceptance of a lifetime 
modeling framework 23. It would be of interest to ask ICER how 
they justify their position on the prospective entry of new 
compounds given their commitment to lifetime cost-utility 
models. 
 
Health Related Quality of Life 
Claims for therapy options couched in terms of quality of life as 
a single metric that combines morbidity and mortality have an 
obvious appeal. The downsides are the questions of the choice 
and acceptability of the particular  instrument together with the 
ability to map or crosswalk from clinical scores or patient 
reported outcomes (PROs) to an agreed standard score 24. 
Unlike NICE in the UK there is no standard for QALY 
measurement in the US to support product claims nor, more to 
the point, is there any interest is collecting QALY measures to 
validate modeled QALY claims by the overwhelming majority of 
health care systems. 
 
Commentary FORMULARY EVALUATIONS 
 
http://z.umn.edu/INNOVATIONS                             2017, Vol. 8, No. 2, Article 10                       INNOVATIONS in pharmacy   5 
 
ICER does not admit a standard for QALY measurement, either 
in terms of a measure’s ability to cover generically a range of 
disease states or its psychometric properties such as Rasch 
interval measurement. In multiple sclerosis the ICER lifetime 
model relies upon an algorithm linking ACR status to utilities; in 
the NICE model the link is to EULAR status.  
 
It is of interest to note that the latest (March 2017) version of 
the Canadian guidelines for health technology assessment 
cautions against accepting uncritically mapping algorithms as 
their ‘predictive value can vary dramatically depending on 
instruments being mapped, the algorithm being used and the 
severity of the health states included’. At the same time, it is 
also worth noting the recent experience with attempting to 
move from the EQ-5D-3L to the purportedly more sensitive EQ-
5D-5L version. Unfortunately, the application of the EQ-5D is 
now in doubt as the attempt to move to a more sensitive 
version of the instrument with five levels within each health 
domain (EQ-5D-5L) as opposed to the three levels (EQ-5D-3L) 
has led to a situation where these two versions produce 
substantially different estimates of cost-effectiveness 25. This is 
because of the combined effect of differences in the way 
individuals respond to the changed descriptive system and the 
changed valuation system in the 5L compared to the 3L. The 
two versions are not consistent with each other. This problem 
is likely to plague NICE for years given the number of accepted 
modeled evaluations and claims for cost-per-QALY outcomes 
based on the EQ-5D-3L. If  ICER, for example, used the EQ-5D-
3L as the multi-attribute utility instrument in accepting the ACR 
mapping algorithm, revising the algorithm to generate EQ-5D-
5L utilities may result in quite different utility scores and cost-
per-QALY projections and price discounting recommendations.  
 
The issue is further compounded by range of available possible 
measures (time-trade off, standard gamble) as well as generic 
multi-attribute instruments (EQ-5D-3L, EQ-5D-5L, HUI, ST-6D) 
and algorithms that have been proposed to map or crosswalk 
items from disease specific patient reported outcomes (PRO) 
instruments or clinical markers to  generic instrument standard. 
Aside, of course, from the possibility that directly measuring 
EQ-5D-5L utilities from a pragmatic TIM sequencing trial may 
generate a different set of utility profiles that may result from 
crosswalking within an EQ-5D-3L framework.  Again, there are 
no evaluable claims from the ICER model that would enable 
health system decision makers to assess the contribution of 
alternative QALY constructs or manufacturers to challenge the 
claims. Claims for QALYs for the various TIM pathways are non-
starters for comparative validation. In challenging ICER, one can 
presumably choose one’s own instrument.   
 
Comorbidities and Symptoms 
Lifetime modeled claims for competing therapy interventions 
typically ignore the presence of comorbidities in modeling 
outcomes in target treating populations. This is a significant 
oversight as the presence of comorbidities, typically present in 
older populations such as the ICER modeled cohort in multiple 
sclerosis, can have a potentially significant impact not only on 
the patient’s quality of life but also on outcomes achieved in the 
target disease state. The importance of managing comorbidities 
in rheumatoid arthritis is seen in the Canadian Dermatology-
Rheumatology Comorbidity Initiative where the point is made 
that comorbidities such as cardiovascular disease can 
‘contribute to increased early mortality, affect disease activity 
and response to treatments, and generate costs in these 
patients’ 26 .  
 
This situation is further compounded by the presence of 
symptoms such as fatigue and pain, together with possible 
depression and anxiety, which may characterize older 
populations. In this context it is worth noting a the systematic 
review and network meta-analysis reported by Jansen et al of 
patient reported outcomes (PROs) in patients with an 
inadequate response to cDMARDs. This review captured a 
range of outcomes including pain, self-reported disease 
activity, functional ability, physical and mental health and 
fatigue within the different classes of bDMARD therapies 27.  
The downside for those who subscribe to the construction of 
imaginary lifetime modeled claims is that attempts to introduce 
comorbidities into a model yield even more scenarios to be 
considered.  At the same time, to put comorbidities to one side 
makes the construction of imaginary scenarios even less 
attractive to the prospective health system audience. It would, 
of course, be possible to factor out only those costs directly 
attributable to rheumatoid arthritis. However, this raises the 
further question of the choice of technique to partition these 
costs. 
 
Adherence and Persistence  
Making assumptions regarding lifetime adherence and 
persistence with therapy and attempting to draw conclusions 
regarding possible differences with competing therapies seems 
a particularly pointless exercise if the assumptions generate 
compliance profiles that are at variance with observed 
behavior. In the ICER model case the assumptions relate not to 
compliance with the initial therapy, but to compliance over the 
potential three sequential TMI therapies in the specific 
pathways. In the ICER model patients discontinued therapy if 
they received an ACR score < 20 in the first six month cycle. 
Beyond six months, discontinuation was due to the occurrence 
of adverse events. As the cycle length was six months this 
presumably occurred at the end of a further six months of 
therapy following an earlier discontinuation. After three TIMs 
the patient is assumed to revert to cDMARD therapy for the rest 
of their life. Patients are apparently not allowed to switch to a 
cDMARD or other palliative care before experiencing at least 18 
months of TIMs.  
 
Unfortunately, and this is acknowledged in the ICER model, 
data for long term persistence with therapy, evidence for 
different patterns of adherence and persistence between the 
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various bDMARDS and evidence for the causes of 
discontinuation and therapy switching are limited, if not non-
existent. In a recent paper, Souto et al go some way towards a 
more complete picture of the prevalence, causes and predictors 
of discontinuation with biologic therapies from a systematic 
review and meta-analysis of drug registries and health care data 
bases 28. In total studies with > 200,000 patients were included 
in the analysis, 81 of which included TNF inhibitors, 14 all 
biologics and 3 abatacept. There were no data on rituximab. 
Overall, 63 European and 35 non-European registries were 
included. The patterns observed pointed to (i) substantial 
differences in persistence behavior between the individual TNK 
inhibitors (etanercept, infliximab, adalimumab, monoclonal 
antibodies) and (ii) substantial variation within each of the 
therapies. At six months, for example, discontinuation of all TNF 
inhibitors was 21% (range 14 to 28%), 27% at 1 year (range 23 
– 32%0 and at 2 years 37% (range 35 – 40%). In the case of 
adalimumab, to give one example again, at six months 
discontinuation was 33% (range 32-35%) and at 2 years 42% (37 
to 47%).  
 
Also noteworthy, is the observation that discontinuation of 
individual TNF inhibitors was significantly higher in patients 
treated after 2005. There was considerable heterogeneity in 
the studies in the contribution of lack of efficacy versus adverse 
events. Predictors of time to discontinuation, for example, 
showed lower discontinuation for any cause in patients treated 
with etanercept versus infliximab or adalimumab. Lower 
discontinuation was associated with concomitant use of 
cDMARDs. Disease duration predicted higher discontinuation 
for adverse events but not for lack of efficacy or any cause. 
Female sex predicted higher discontinuation for any cause. 
 
Given the contribution of drug costs to overall assessments of 
cost-effectiveness among competing TIMs, it would be far more 
useful from a formulary decision perspective to avoid modeled 
claims that attempt to capture persistence and switching 
behavior over the lifetimes of a hypothetical cohort of patients, 
focusing instead on short-term models where claims for 
persistence and the relative contributions of adverse events 
and efficacy can be evaluated for competing therapies. 
Presumably, manufacturers would want to put forward claims 
for fewer adverse events and improved efficacy to support 
value claims for persistence with their products. With the 
observed heterogeneity observed in persistence patterns, it 
would seem more useful to focus on shorter term impacts that 
can be evaluated and replicated in target populations, to 
include the contribution of polytherapy due to comorbid 
conditions, rather than make unsupported assumptions 
regarding long term persistence in a range of treatment 
pathways  when the majority of patients may have abandoned 
bDMARD therapies within 2 to 3 years.. Manufacturers could 
also be encouraged to propose intervention and patient 
management strategies to support their product and standards 
for the choice of successor therapies.  
 
Drug Prices 
The ICER evidence report recognizes that the prices of TIMS 
have risen substantially. The evidence report cites two TIMS 
with the leading market share, adalimumab and etanercept, 
having risen in price by 70-80% in last 3 years which, even 
allowing for discounts, rebates or patient assistant programs is 
still substantial. Given this, it seems odd that ICER has not 
apparently attempted to build into the model assumptions 
regarding expected WAC price increases, together with 
projected price increases for the other cost components, for 
the individual TIMs over the anticipated treatment lifetime. 
After all, if prices increase for selected TIMs at 15% per annum, 
compounded over five years the WAC price will have almost 
doubled. A situation that is further compounded by the 
possibility that annualized price increases may vary between 
the respective TIMs.  
 
Model Validation 
The ICER evidence review also reports on steps taken to 
validate the model. This is achieved, apart from internally 
evaluating mathematical functions, by comparing the model to 
other models which were similar in hypothetical populations, 
setting, perspective and treatments. In effect, comparing one 
imaginary construct to other imaginary constructs; one set of 
facts with alternative facts. At best, in the absence of any 
commitment to generating and testing evaluable claims, this 
serves to demonstrate the inadvisability of actually committing 
to the construction of imaginary worlds: models generate 
different outcomes because the models are, well, different. 
Presumably this sets the stage for even more imaginary lifetime 
rheumatoid arthritis constructs; a plethora of imaginary worlds 
with non-evaluable claims. Of course, this is in the 
pharmacoeconomic tradition with literally thousands of 
modeled non-evaluable therapy claims published in the leading 
health care technology journals over the past 30 years 29 30 31. 
 
An Alternative Perspective 
Although this is not an endorsement of the ICER model, it is 
possible with estimates provided in the evidence review for 
treatment pathway costs and outcomes to put a quite different 
perspective on drug pricing and recommendations for 
discounting. As detailed above, Table 1 presents the base-case 
ICER modeled estimates of TIM pathway lifetime treatment 
costs by initial second line therapy for those who have failed 
prior cDMARD therapy. However, rather than considering the 
implications for drug pricing by constructing ICERs referenced 
by the cDMARD therapy pathway, we can consider a 
comparison, not of incremental costs and QALY gain over 
cDMARD but on the projected lifetime costs of each of the TIM 
treatment pathways compared to lifetime QALYs. This yields a 
cost-per-QALY projection for each pathway. The results are 
presented in Table 1 as (i) costs per life year; (ii) costs per QALY 
and (iii) costs-per-QALY differences from the average cost-per-
QALY for the 12 TIM pathways. 
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From this perspective, a formulary committee has to judge 
whether it is prepared to pay, on average, $39,682 (at current 
prices) for each QALY. Rather than the somewhat artificial and 
self-serving comparison (from a price discounting perspective) 
of the additional cost-per-QALY gained over traditional 
cDMARDs, where the result is a foregone conclusion. This  more 
pragmatic perspective considers what it will cost in life years 
and quality of life to introduce those failing or non-responsive 
to cDMARDs to any one of the TIM pathways. In this case, the 
differences in cost-per-QALY compared to the average (or to 
any other reference TIM such as adalimumab) range from a 
‘gain’ of $4,788 for etanercept to a ‘loss’ with tocilizumab (sc) 
of $6,350. For those who subscribe to willingness-to-pay 
thresholds, all of the TIMs come in under $50,000 per QALY at 
current prices. If we accept the results of the ICER model then 
the choice in cost-per-QALY terms is the tocilizumab (sc) 
treatment pathway; total projected cost (subject to the caveats 
considered above) is the lowest, while the life-years and QALYs 
are essentially no different from the competing TIM pathways.  
 
Conclusions 
It is not the intent here to suggest how the ICER model can be 
‘improved’. The position taken is that in emulating NICE, in 
focusing on lifetime cost per QALY models as the standard for 
evaluating competing therapies and making recommendations 
for price discounting, the ICER approach is simply misplaced; it 
is a pointless exercise. The construction of lifetime cost-per-
QALY models is unacceptable, if we subscribe to the standards 
of normal science, because the claims are unevaluable. More to 
the point: they were never intended to be evaluated. However 
much we may tinker with the core model through the 
construction of alternative scenarios, assumptions about long 
term therapy choice and response to therapy, the methodology 
is insupportable. 
 
Rather than attempting to inform decision makes through the 
construction of imaginary worlds, price negotiations should be 
predicated on evidence that meets the standards of normal 
science. Unless evaluable and replicable claims are presented 
by ICER to support recommendations for price discounting, the 
recommendations should be rejected. This applies not only to 
the current recommendations for price discounting of TIMs, but 
to other ICER evidence reviews that have generated non-
evaluable claims. If we reject relativism in favor of  the 
standards of normal science, the only acceptable claims are 
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ICER Multiple Sclerosis Model: Costs per QALY and Incremental QALYs for Base Case  




























Rituximab 464,864 78.90 16.79 12.70 -32.54 27,687 36,603 -3,078 
Abatacept 
(iv) 
466,733 78.79 16.82 12.78 -3.34 27,749 36,520 -3,162 
Abatacept 
(sc) 
566,053 79.90 16.87 12.90   0.45 33,554 43,880 4,198 
Tocilizumab 
(iv) 
470,205 78.66 16.85 12.88   33.15 27,905 36,506 3,176 
Tocilizumab 
(sc)* 
424,674 77.55 16.83 12.81    7.06 25,233 
 
33,152 6,530 
Tofacitinib 579,140 80.77 16.78 12.57 -80.00 34,493 
 
46,073 -6,391 
Adalimumab 530,720 80.20 16.78 12.68 -39.85 31,628 41,855 -2,172 
Certolizuma
b pegol 
522,473 79.95 16.84 12.86   25.85 31,025 40,628 -946 





512,875 79.63 16.79 12.69 -36.20 30,547 36,632 3,050 
Golimumab 
(iv) 
488,380 79.24 16.81 12.75 -14.30 29,053 38,304 1,378 
Infliximab 480,448 79.54 16.79 12.73 -21.60 28,615 37,741 1,941 
         
Average 507,501 79.50 16.82 12.79  30,164 39,682  
         
cDMARD 67,819 26.85 16.16 10.69 2.10* 4,197 6,344 -33,338** 
 
Note: Treatment pathway as defined in ICER model following previous failure on cDMARDs and initiated with combination therapy 
(MTX + bDMARD/TIM). The simulated life years/QALYs together with simulated total costs and drug costs are from initiation of 
combination therapy for the treatment pathway over the projected lifetime of the hypothetical cohort. * versus average QALYs for 
TIMs. ** versus average cost per QALY for TIMs. 














Commentary FORMULARY EVALUATIONS 
 
http://z.umn.edu/INNOVATIONS                             2017, Vol. 8, No. 2, Article 10                       INNOVATIONS in pharmacy   9 
 
References 
1 Institute for Clinical and Economic Review (ICER). Targeted Immune Modulators for rheumatoid Arthritis: Effectiveness and Value.: 
Evidence Report. April 2017 
 
2 Langley PC. Cost-Effectiveness and Formulary Evaluation: Imaginary Worlds and Entresto Claims in Heart Failure. Inov Pharm. 
2016;7(3): No. 6 
 
3 Langley PC. Multiple Sclerosis and the Comparative Value Disease Modifying Therapy Report of the Institute for Clinical and 
Economic Review (ICER). Inov Pharm. 2017;8(1): No. 12 
 
4 Langley PC. Intelligent Design and Imaginary Worlds in Cost-Effectiveness Claims: An Overview of Commentaries in INNOVATIONS 
in Pharmacy from July 2016 to February 2017. Inov Pharm. 2017;8(1): No. 22 
 
5 Pigliucci M. Nonsense on stilts: How to tell science from bunk. Chicago: University of Chicago Press, 2010 
 
6 Langley PC. Nullius in verba: Version 2.0 of the University of Minnesota, School of Social and Administrative Pharmacy Program, 
Proposed Guidelines for Formulary Evaluation. Inov Pharm.2016;7(4): No.16 
 
7 University of Minnesota. Program in Social and Administrative Pharmacy. Guidelines for Formulary Evaluations [Proposed]. Version 
2.0. December 2016 https://www.pharmacy.umn.edu/sites/pharmacy.umn.edu/files/minnesota_guidelines_december_2016.pdf 
  
8 Sweet B, Tadlock CG, Waugh W, et al. The WellPoint outcomes based formulary: enhancing the health technology assessment 
process. J Med Econ 2005;8:13-25 
 
9 Langley PC. Recent developments in the health technology assessment process in Fulda TR, Wertheimer AI, eds. Handbook of 
Pharmaceutical Public Policy. New York: Pharmaceutical Products Press, 2007 
 
10 Stevenson M, Archer R, Tosh J et al. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and 
abatacept for the treatment of rheumatoid arthritis not previously treated with disease modifying antirheumatic drugs and after the 
failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Health Tech Assess. 
2016;20(35):1-610 
 
11 Donahue K, Jonas D, Hansen R et al. Drug therapy for rheumatoid arthritis in adults: An Update. Comparative Effectiveness Review 
No. 55Rockville MD: Agency for Healthcare Research and Quality. April 2012 
 
12 Singh J, Hossain A, Tanjong E et al. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or 
other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. Cochrane Database Syst 
Rev. 2016(5) 
   
13 Singh J, Hossain A, Tanjung E.. Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-
modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA). Cochrane 
Database Syst Rev. 2016(11)  
 
14 Canadian Agency for Drugs and Technologies in Health. Clinical and Economic Overview: Biological Response Modifier Agents for 
Adults with Rheumatoid Arthritis. Ottawa: CADTH, 2010 
 
16 National Institute for Health and Care Excellence (NICE). Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, 
tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDS or after conventional DMARDs only have 
failed. Technology Appraisal Guidance (TA375). London: NICE, 2017 
 
17 Langley PC. Supporting Formulary Decisions: The Discovery of New Facts or Constructed Evidence?. Inov Pharm. 2016;7(2): No. 15 
 
18 Wootton D. The Discovery of Science. New York: Harper Collins, 2015 
                                                 
Commentary FORMULARY EVALUATIONS 
 
http://z.umn.edu/INNOVATIONS                             2017, Vol. 8, No. 2, Article 10                       INNOVATIONS in pharmacy   10 
 




20 Canadian Agency for Drugs and Technologies in Health (CADTH). Guidelines for the Economic Evaluation of Health Technologies: 
Canada (4th Ed.). Ottawa:March 2017 
 
21 Langley PC. True North: Building imaginary worlds with the revised Canadian (CADTH) Guidelines for Health Technology 
Assessment. Inov Pharm. 2017;8(2): No. 9  
 
22 Langley PC, Rhee TG. Imaginary Worlds: The Status of Simulation Modeling in Claims for Cost-Effectiveness in Diabetes Mellitus. 
Inov Pharm. 2016;7(2): No. 17. 
 
23 Langley PC. Sunlit Uplands: The Genius of the NICE Reference Case. Inov Pharm. 2016;7(2): No. 12 
 
24 Langley PC. Great Expectations: Cost-Utility Models as Decision Criteria. Inov Pharm. 2016;7(2): No. 14 
 
25 National Institute for Health and Care Excellence. Decision Support unit. Comparing the EQ-5D-3L and 5L versions. What are the 
implications for cost-effectiveness estimates? NICE: March, 2017 
http://www.nicedsu.org.uk/USERIMAGES/DSU_3L%20to%205L%20FINAL.pdf 
 
26 Roubille C, Richer V, Starnino T et al. Evidence-based recommendations for the management of comorbidities in rheumatoid 
arthritis, psoriasis, and psoriatic arthritis: Expert opinion of the Canadian Dermatology-Rheumatology Comorbidity Initiative. J 
Rheumatol. 2015;42:1767-80 
  
27 Jansen J, Buckley F, Dejonckheere f et al. Comparative efficacy of biologics as monotherapy in combination with methotrexate on 
patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDS – a 
systematic review and meta-analysis. Health Qual Life Outcomes. 2014;12:102 
 
28 Souto A, Maneiro J, Gómez-Reino J. Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a 
systematic review and meta-analysis of drug registries and health care databases. Rheumatology. 2016;55:523-534 
 
29 Langley PC. Imaginary Worlds: Modeled claims for cost-effectiveness published in PharmacoEconomics January 2015 to December 
2015. Inov Pharm. 2016;7(2): No. 9 
 
30 Langley PC, Rhee T. Imaginary Worlds: A Systematic Review of the Status of Modeled Cost-Effectiveness Claims Published in the 
Journal of Medical Economics from January 2015 to December 2015. Inov Pharm. 2016;7(2): No. 16 
 
31 Langley PC, Rhee T. Imaginary Worlds: The Status of Modeled Economic Evaluation Claims Published in Value in Health January 
2015 to December 2015. Inov Pharm. 2016;7(2): No. 18 
